Viral Vectors And Plasmid DNA Manufacturing Market (By Type: Adeno associated virus, Lentivirus, Adenovirus, Retrovirus, Plasmid DNA; By Workflow: Upstream Processing, Downstream Processing; By Application: Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology, Research Applications; By End-Use: Pharmaceutical and Biopharmaceutical Companies, Research Institutes; By Disease: Cancer, Genetic Disorders, Infectious Diseases, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

The global Viral Vectors And Plasmid DNA Manufacturing market size is expected to be worth around US$ 10.6 billion by 2030, according to a new report by Vision Research Reports.

The global Viral Vectors And Plasmid DNA Manufacturing market size was valued at US$ 3.billion in 2020 and is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.

Growth Factors

Amidst the COVID-19 pandemic, the demand for viral vectors has rapidly increased especially in vaccinology. This led to expanding manufacturing capabilities by operating players to meet the growing demand. The application of these vectors in vaccine development has witnessed significant growth in 2020.

Also, an increase in the number of gene therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive the demand for scalable production of gene therapy vectors. Owing to this, several private and public agencies are providing funds to accelerate advancements in the manufacturing processes for viral vectors.

Besides, the implementation of single-use technology can lead to significant savings in capital, operating costs, materials, and labor. The use of this equipment will enhance efficiency and improve flexibility, leading to high yields of the final product. Thus, advancements in single-use technology directly impact revenue growth in this space.

Report Highlights

 The Adeno Associated Virus (AAV) segment dominated the market for viral vectors and plasmid DNA manufacturing and accounted for the largest revenue share of 20.0% in 2020. The growing demand and their usage in clinical trials owing to the highest accuracy in delivering the gene to the region of interest has impacted the revenue generation in this segment. The usage of AAV is rising considerably, consequently witnessing a significant boost in the adoption rate. Proven records of non-pathogenicity have boosted their adoption.

Furthermore, Adenoviral vectors are considered safe, thus are increasingly being employed across various research settings. ADV vectors are extensively being used as vaccines as they are capable of inducing strong humoral and T cell responses. Studies based on adenovirus vector as a delivery tool for CRISPR/Cas9 have resulted in effective gene disruption in the host genome of various human cells.

On the other hand, Oxford Biomedica Plc has an exclusive lentivector platform, safe and advanced gene delivery system capable of carrying payloads of up to 9kb. Such advanced products would supplement the segment revenue growth. The success of lentiviral-based gene therapy products has augmented the adoption of these vectors across several end-users.

The downstream processing segment dominated the market for viral vectors and plasmid DNA manufacturing and accounted for the largest revenue share of 55.0% in 2020. To fulfill the requirement of a polished and purified clinical-grade final product, several highly complex procedures are deployed. The introduction of technologically advanced chromatography products and the development of novel technologies to serve fill-finish processing for vector manufacturing has propelled revenue generation.

Implementation of Single-use Technology (SUT) in viral vector manufacturing workflow has also resulted in cost and time-saving procedures. For instance, scalable SUT such as membrane-based ion-exchange chromatography, direct-flow filtration (depth and sterile), and Tangential-flow Filtration (TFF) can be employed for the purification of viral vectors.

the vaccinology segment dominated the market for viral vectors and plasmid DNA manufacturing and accounted for the largest revenue share of 30.9% in 2020. This can be attributed to the high employment of viral vectors in vaccine development owing to their efficiency-related advantages. Some advantages are the potential to elicit a wide immune response, safety profiles, and easy manufacturing.

The recent outbreak of the COVID-19 virus has driven the use of viral vectors in vaccine development. Although viral vectors were widely used for vaccine development before the emergence of COVID-19, the urgency to develop a vaccine against this virus has led the scientific community to repurpose the existing approaches. Non-replicating viral vectors are being used in the COVID-19 viral vector vaccines.

The research institutes segment dominated the market for viral vectors and plasmid DNA manufacturing and accounted for the largest revenue share of 59.0% in 2020. The increasing involvement of the research community in gene and cell therapy research activities is expected to increase the demand for viral vectors in the global market. Maine Medical Center Research Institute, National Institute for Physiological Sciences, and the Viral Vector Core (VVC) are some research institutes that are engaged in the production of vectors.

the cancer segment dominated the market for viral vectors and plasmid DNA manufacturing and accounted for the largest revenue share of 37.0%. Viruses have proven their efficiency as an ideal vector for gene therapy production against various cancer types. Also, the success of viral vector-based CAR-T cell therapies for hematologic malignancies such as mantle cell lymphoma and B-cell lymphoma has gained the attention of end-users.

Gene therapy also focuses on the treatment of rare genetic disorders like hemophilia, Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID), and Lipoprotein Lipase Deficiency (LPLD. There are many private and public companies in the U.S. that are focusing on these disease categories, thus, positively impacting the segment growth.

North America dominated the viral vectors and plasmid DNA manufacturing market and accounted for the largest revenue share of 51.0% in 2020. The presence of a substantial number of centers and institutes that are engaged in the R&D of advanced therapies is one of the key contributing factors for the dominance of the region. With the increasing regulatory approvals for advanced therapies, the U.S. significantly contributed to the regional revenue generation.

Key Players

  • Novasep
  • Aldevron
  • MerckWaismanBiomanufacturing
  • Creative Biogene
  • The Cell and Gene Therapy Catapult
  • Cobra Biologics
  • uniQure N.V.
  • Addgene
  • FUJIFILM Holdings Corporation
  • Oxford Biomedicaplc
  • Takara Bio Inc. 

Market Segmentation

 By Vector Type Outlook 

  • Adenovirus

  • Retrovirus

  • Plasmid DNA

  • AAV

  • Lentivirus

  • Others

By Workflow Outlook 

  • Upstream Processing

    • Vector Amplification & Expansion

    • Vector Recovery/Harvesting

  • Downstream Processing

    • Purification

    • Fill-finish

By Application Outlook 

  • Antisense & RNAi

  • Gene Therapy

  • Cell Therapy

  • Vaccinology

By End-use Outlook 

  • Pharmaceutical and Biopharmaceutical Companies

  • Research Institutes

By Disease Outlook

  • Cancer

  • Genetic Disorders

  • Infectious Diseases

  • Others

By Regional Outlook 

  • North America

    • U.S.

    • Canada
  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

  • Middle East & Africa

    • South Africa

The Viral Vectors And Plasmid DNA Manufacturing market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

The report provides size (in terms of volume and value) of Viral Vectors And Plasmid DNA Manufacturing market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

This report focuses on the global Viral Vectors And Plasmid DNA Manufacturing market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Viral Vectors And Plasmid DNA Manufacturing market development in United States, Europe and China.

It is pertinent to consider that in a volatile global economy, we haven’t just conducted Viral Vectors And Plasmid DNA Manufacturing market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.

In terms of production side, this report researches the Viral Vectors And Plasmid DNA Manufacturing capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.

In terms of consumption side, this report focuses on the consumption of Viral Vectors And Plasmid DNA Manufacturing by regions (countries) and application.

Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Viral Vectors And Plasmid DNA Manufacturing market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.

With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Viral Vectors And Plasmid DNA Manufacturing market companies.

Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Viral Vectors And Plasmid DNA Manufacturing market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.

The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.

Overall, this is an in-depth research report specifically for the Viral Vectors And Plasmid DNA Manufacturing industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.

Viral Vectors And Plasmid DNA Manufacturing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Viral Vectors And Plasmid DNA Manufacturing market.

Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Viral Vectors And Plasmid DNA Manufacturing market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.

Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Viral Vectors And Plasmid DNA Manufacturing market. These factors have benefited the growth of the global market for Viral Vectors And Plasmid DNA Manufacturing. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.

New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Viral Vectors And Plasmid DNA Manufacturing. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).

In this study, the years considered to estimate the market size of Viral Vectors And Plasmid DNA Manufacturing are as follows:

  • History Year: 2017-2020
  • Base Year: 2020
  • Forecast Year 2021 to 2030

Reasons to Purchase this Report:


- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Market Size Estimation

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).

The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.

Secondary Sources

Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2017-2020) and forecast (2021-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Chapter 1. Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1.  Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type, 2020-2027

7.1.1.    Adenovirus

7.1.1.1.        Market Revenue and Forecast (2016-2027)

7.1.2.    Retrovirus

7.1.2.1.        Market Revenue and Forecast (2016-2027)

7.1.3.    Plasmid DNA

7.1.3.1.        Market Revenue and Forecast (2016-2027)

7.1.4.    AAV

7.1.4.1.        Market Revenue and Forecast (2016-2027)

7.1.5.    Lentivirus

7.1.5.1.        Market Revenue and Forecast (2016-2027)

Chapter 8.  Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

8.1.  Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type, 2020-2027

8.1.1.    Upstream Processing

8.1.1.1.        Market Revenue and Forecast (2016-2027)

8.1.2.    Downstream Processing

8.1.2.1.        Market Revenue and Forecast (2016-2027)

Chapter 9.  Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

9.1.  Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type, 2020-2027

9.1.1.    Antisense & RNAi

9.1.1.1.        Market Revenue and Forecast (2016-2027)

9.1.2.    Gene Therapy

9.1.2.1.        Market Revenue and Forecast (2016-2027)

9.1.3.    Cell Therapy

9.1.3.1.        Market Revenue and Forecast (2016-2027)

9.1.4.    Vaccinology

9.1.4.1.        Market Revenue and Forecast (2016-2027)

Chapter 10.      Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-use Type

10.1.        Viral Vectors & Plasmid DNA Manufacturing Market, By End-use Type, 2020-2027

10.1.1.  Pharmaceutical and Biopharmaceutical Companies

10.1.1.1.      Market Revenue and Forecast (2016-2027)

10.1.2.  Research Institutes

10.1.2.1.      Market Revenue and Forecast (2016-2027)

Chapter 11.      Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease Type

11.1.        Viral Vectors & Plasmid DNA Manufacturing Market, By Disease, 2020-2027

11.1.1.  Cancer

11.1.1.1.      Market Revenue and Forecast (2016-2027)

11.1.2.  Genetic Disorders

11.1.2.1.      Market Revenue and Forecast (2016-2027)

11.1.3.  Infectious Diseases

11.1.3.1.      Market Revenue and Forecast (2016-2027)

Chapter 12.      Global Viral Vectors & Plasmid DNA Manufacturing  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.1.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.1.3.  Market Revenue and Forecast, By Application (2016-2027)

12.1.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.1.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.1.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.1.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.1.6.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.1.7.  Market Revenue and Forecast, By Disease (2016-2027)

12.1.8.  Rest of North America

12.1.8.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.1.8.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.1.8.3.      Market Revenue and Forecast, By Application (2016-2027)

12.1.8.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.1.8.5.      Market Revenue and Forecast, By Disease (2016-2027)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.2.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.2.3.  Market Revenue and Forecast, By Application (2016-2027)

12.2.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.2.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.2.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.2.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.2.7.  Market Revenue and Forecast, By End-use (2016-2027)

12.2.8.  Market Revenue and Forecast, By Disease (2016-2027)

12.2.9.  Germany

12.2.9.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.2.9.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.2.9.3.      Market Revenue and Forecast, By Application (2016-2027)

12.2.10.               Market Revenue and Forecast, By End-use (2016-2027)

12.2.11.               Market Revenue and Forecast, By Disease (2016-2027)

12.2.12.               France

12.2.12.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.2.12.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.2.12.3.   Market Revenue and Forecast, By Application (2016-2027)

12.2.12.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.2.13.               Market Revenue and Forecast, By Disease (2016-2027)

12.2.14.               Rest of Europe

12.2.14.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.2.14.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.2.14.3.   Market Revenue and Forecast, By Application (2016-2027)

12.2.14.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.2.15.               Market Revenue and Forecast, By Disease (2016-2027)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.3.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.3.3.  Market Revenue and Forecast, By Application (2016-2027)

12.3.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.3.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.3.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.3.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.3.6.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.3.7.  Market Revenue and Forecast, By Disease (2016-2027)

12.3.8.  China

12.3.8.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.3.8.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.3.8.3.      Market Revenue and Forecast, By Application (2016-2027)

12.3.8.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.3.9.  Market Revenue and Forecast, By Disease (2016-2027)

12.3.10.               Japan

12.3.10.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.3.10.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.3.10.3.   Market Revenue and Forecast, By Application (2016-2027)

12.3.10.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.3.10.5.   Market Revenue and Forecast, By Disease (2016-2027)

12.3.11.               Rest of APAC

12.3.11.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.3.11.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.3.11.3.   Market Revenue and Forecast, By Application (2016-2027)

12.3.11.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.3.11.5.   Market Revenue and Forecast, By Disease (2016-2027)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.4.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.4.3.  Market Revenue and Forecast, By Application (2016-2027)

12.4.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.4.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.4.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.4.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.4.6.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.4.7.  Market Revenue and Forecast, By Disease (2016-2027)

12.4.8.  North Africa

12.4.8.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.4.8.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.4.8.3.      Market Revenue and Forecast, By Application (2016-2027)

12.4.8.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.4.9.  Market Revenue and Forecast, By Disease (2016-2027)

12.4.10.               South Africa

12.4.10.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.4.10.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.4.10.3.   Market Revenue and Forecast, By Application (2016-2027)

12.4.10.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.4.10.5.   Market Revenue and Forecast, By Disease (2016-2027)

12.4.11.               Rest of MEA

12.4.11.1.   Market Revenue and Forecast, By Vector (2016-2027)

12.4.11.2.   Market Revenue and Forecast, By Workflow (2016-2027)

12.4.11.3.   Market Revenue and Forecast, By Application (2016-2027)

12.4.11.4.   Market Revenue and Forecast, By End-use (2016-2027)

12.4.11.5.   Market Revenue and Forecast, By Disease (2016-2027)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, By Vector (2016-2027)

12.5.2.  Market Revenue and Forecast, By Workflow (2016-2027)

12.5.3.  Market Revenue and Forecast, By Application (2016-2027)

12.5.4.  Market Revenue and Forecast, By End-use (2016-2027)

12.5.5.  Market Revenue and Forecast, By Disease (2016-2027)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.5.6.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.5.6.3.      Market Revenue and Forecast, By Application (2016-2027)

12.5.6.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.5.7.  Market Revenue and Forecast, By Disease (2016-2027)

12.5.8.  Rest of LATAM

12.5.8.1.      Market Revenue and Forecast, By Vector (2016-2027)

12.5.8.2.      Market Revenue and Forecast, By Workflow (2016-2027)

12.5.8.3.      Market Revenue and Forecast, By Application (2016-2027)

12.5.8.4.      Market Revenue and Forecast, By End-use (2016-2027)

12.5.8.5.      Market Revenue and Forecast, By Disease (2016-2027)

Chapter 13.  Company Profiles

13.1.              Novasep

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              Aldevron

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              MerckWaismanBiomanufacturing

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              Creative Biogene

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              The Cell and Gene Therapy Catapult

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              Cobra Biologics

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              uniQure N.V.

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              Addgene

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              FUJIFILM Holdings Corporation

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           Oxford Biomedicaplc

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

13.11.           Takara Bio Inc.

13.11.1.               Company Overview

13.11.2.               Product Offerings

13.11.3.               Financial Performance

13.11.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1. About Us

15.2 Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers